THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY published The State of Cancer Care in America: 2016, in the Journal of Oncology Practice—ASCO’s third annual assessment of national trends in cancer care delivery. The report was also presented at a Congressional briefing in Washington, D.C., The report highlights many promising cancer care developments, including new drugs and...
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
